HMG-CoA reductase inhibitors are used to reduce the risk of death from cardiovascular disease in chronic kidney disease patients, as the inhibition of mevalonate production reduces total cholesterol and low-density lipoprotein cholesterol34. This evidence concerns the gene HMGCR and cardiovascular disorder.